Mark James Litton Sells 2,586 Shares of Athira Pharma (NASDAQ:ATHA) Stock

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 2,586 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $6.88, for a total value of $17,791.68. Following the sale, the chief executive officer directly owned 40,828 shares of the company’s stock, valued at approximately $280,896.64. This represents a 5.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Athira Pharma Trading Up 5.6%

Shares of ATHA stock opened at $6.95 on Wednesday. The company has a market capitalization of $27.38 million, a P/E ratio of -0.72 and a beta of 2.79. The business’s 50 day moving average is $5.08 and its two-hundred day moving average is $4.29. Athira Pharma, Inc. has a twelve month low of $2.20 and a twelve month high of $8.36.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($1.51). As a group, equities analysts predict that Athira Pharma, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Athira Pharma

An institutional investor recently raised its position in Athira Pharma stock. BML Capital Management LLC increased its holdings in Athira Pharma, Inc. (NASDAQ:ATHA) by 0.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,230,667 shares of the company’s stock after buying an additional 30,000 shares during the period. Athira Pharma comprises about 0.7% of BML Capital Management LLC’s holdings, making the stock its 17th largest position. BML Capital Management LLC owned about 8.27% of Athira Pharma worth $976,000 at the end of the most recent quarter. 57.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ATHA has been the subject of a number of recent analyst reports. Mizuho set a $4.00 price objective on shares of Athira Pharma in a research report on Friday, September 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell” and a consensus price target of $4.00.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.